Global transcriptomic analysis of endocrine therapy-resistant breast cancer cells revealed that SLC6A14 expression is downregulated under the control of increased miR-23b-3p expression, resulting in increased aspartate and glutamate uptake (Bacci et al., 2019). The gene discussed is SLC6A14; the disease is breast cancer.